甲状腺毒症与甲状腺结节的分子影像
本文综述甲状腺分子影像在甲状腺毒症和甲状腺结节中的应用。摄碘率测定联合闪烁显像可鉴别破坏性与产热性甲状腺毒症,并定位自主功能性结节;MIBI与18F-FDG可辅助细胞学不确定冷结节的良恶性判断,摄碘率还可用于计算131I治疗活度。
要点
- 摄碘率测定联合123I或99mTcO4-闪烁显像可鉴别甲状腺毒症病因。
- 自主功能性甲状腺结节可安全免于细针穿刺活检。
- MIBI与18F-FDG可辅助细胞学不确定冷结节的评估。
核心结论
- 甲状腺分子影像可表征不同甲状腺疾病的分子与功能特征,并在临床症状出现前进行评价。
- 甲状腺分子影像是恰当管理甲状腺毒症与甲状腺结节不可或缺的组成部分。
研究设计与样本
- 本文为综述,总结甲状腺分子影像的基本概念、临床应用与潜在发展方向。
主要发现
- 排除外源性碘负荷后,123I或131I摄碘率测定可准确评估和量化甲状腺细胞内碘摄取与动力学。
- 123I或99mTcO4-闪烁显像可提供甲状腺细胞活性的拓扑分布,并检测和定位异位甲状腺组织。
- 破坏性甲状腺毒症表现为摄碘率消失或降低,产热性甲状腺毒症表现为高摄碘率伴闪烁显像弥漫性或局灶性过度活跃。
- 99mTc-MIBI与18F-FDG可补充细胞学不确定冷结节的检查,并有助于减少诊断性腺叶切除/甲状腺切除的需要。
- 摄碘率研究可用于计算131I治疗甲状腺功能亢进和甲状腺功能正常的多结节性甲状腺肿的治疗活度。
关键数值与推荐
- 破坏性甲状腺毒症以摄碘率消失或降低为特征。
- 产热性甲状腺毒症以高摄碘率伴闪烁显像弥漫性(Graves病和弥漫性甲状腺自主)或局灶性(自主功能性甲状腺结节)过度活跃为特征。
- 自主功能性甲状腺结节可安全排除于细针穿刺活检之外。
临床怎么用
- 对甲状腺毒症患者,在排除外源性碘负荷后可用摄碘率测定和/或闪烁显像鉴别病因。
- 对细胞学不确定的冷结节,可考虑99mTc-MIBI或18F-FDG辅助评估以降低诊断性手术需求。
- 对计划131I治疗甲状腺功能亢进或甲状腺功能正常的多结节性甲状腺肿者,可用摄碘率研究计算治疗活度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
After exclusion of exogenous iodine overload, radioiodine uptake (RAIU) testing with 123I or 131I enables the accurate evaluation and quantification of iodine uptake and kinetics within thyroid cells. In addition, scintigraphic evaluation with 123I or 99mTc-pertechnetate (99mTc04-) provides the topographic distribution of thyroid cell activity and allows the detection and localization of ectopic thyroid tissue. Destructive thyrotoxicosis is characterized by abolished or reduced uptake whereas productive thyrotoxicosis (i.e., hyperthyroidism "sensu strictu") is characterized by high RAIU with scintigraphically diffuse (i.e., Graves disease and diffuse thyroid autonomy) or focal (i.e., autonomously functioning thyroid nodules [AFTN]) overactivity. Accordingly, RAIU or thyroid scintigraphy are widely used to differentiate different causes of thyrotoxicosis. In addition, several radiopharmaceuticals are also available to help in differentiating benign from malignant thyroid nodules and inform clinical decision making. In fact, AFTNs can be safely excluded from fine-needle aspiration biopsy while either 99mTc-methoxyisobutylisonitrile (MIBI) and 18F-FDG may complement the work-up of cytologically indeterminate cold nodules and contribute to reducing the need for diagnostic lobectomies/thyroidectomies. Finally, RAIU studies are also useful for calculating the administered therapeutic activity of 131I to treat hyperthyroidism and euthyroid multinodular goiter. All considered, thyroid molecular imaging allows us to characterize molecular/functional aspects of different thyroid diseases, even before clinical symptoms become manifest and remains integral to properly managing such conditions. Our present paper summarizes basic concepts, clinical applications, and potential developments of thyroid molecular imaging in patients affected by thyrotoxicosis and thyroid nodules.
引用
- Giovanella L, Avram A, Clerc J, et al. Molecular Imaging for Thyrotoxicosis and Thyroid Nodules. J Nucl Med. 2021. PMID: 34230069. doi:10.2967/jnumed.120.246017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。